The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The industry rank for Xlife Sciences AG's 14-Day RSI or its related term are showing as below:
CHIX:XLSz's 14-Day RSI is ranked better than 92.18% of 1420
companies
in the Biotechnology industry
Industry Median: 48.885
vs CHIX:XLSz: 32.76
Xlife Sciences AG (CHIX:XLSz) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Xlife Sciences AG 14-Day RSI Related Terms
CHIX:XLSZ vs VRTX, REGN, ALNY: 14-Day RSI Comparison
For the Biotechnology subindustry, Xlife Sciences AG's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's 14-Day RSI falls into.
Xlife Sciences AG (CHIX:XLSz) 14-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xlife Sciences AG (CHIX:XLSZ) has a 14-Day RSI of 32.76 as of Jul. 11, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Xlife Sciences AG and its competitors. According to the industry distribution chart, Xlife Sciences AG ranks #111 out of 1420 companies in the Biotechnology industry, placing it in the top 7.8%.
Is Xlife Sciences AG's 14-Day RSI too high?
Xlife Sciences AG's current 14-Day RSI is 32.76. The Biotechnology industry median 14-Day RSI is 48.89. Xlife Sciences AG's value of 32.76 is 33% below this industry median. Based on the distribution chart, Xlife Sciences AG ranks #111 out of 1420 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Xlife Sciences AG has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xlife Sciences AG ranks #111 out of 1420 companies for 14-Day RSI. This places Xlife Sciences AG in the top 8% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 48.89. Xlife Sciences AG's value of 32.76 is 33% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 48.89, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xlife Sciences AG's current 14-Day RSI of 32.76 is 33% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Xlife Sciences AG and its competitors. For the Biotechnology industry, the median 14-Day RSI is 48.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xlife Sciences AG's current 14-Day RSI is 32.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (CHIX:XLSZ) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.17, compared to a current price of CHF18.30 — trading 155.2% above its estimated fair value. The current 14-Day RSI is 32.76 and 33% below the Biotechnology industry median of 48.89. Xlife Sciences AG's overall GF Score™ is 37/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Xlife Sciences AG (CHIX:XLSZ), the current 14-Day RSI is 32.76 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (CHIX:XLSZ) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of CHF18.30 is trading 155.2% above its estimated GF Value™ of CHF7.17.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for CHIX:XLSZ:
14-Day RSI: 32.76
GF Value™: CHF7.17 vs. price of CHF18.30 (155.2% above fair value)
Industry Position: 33% below the Biotechnology median (#111 of 1420)
No single metric tells the full story. See the CHIX:XLSZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
37GF Score
Get the complete analysis for CHIX:XLSZ
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:XLSZ has been successfully added to your 